Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden muscle loss may affect ovarian cancer treatment

NCT ID NCT05415527

Knowledge-focused Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study checks for muscle loss (sarcopenia) in 25 women with advanced ovarian cancer before they start chemotherapy. Using CT scans, researchers want to see how common this condition is and if it affects treatment timing. The goal is to better understand how muscle health relates to cancer care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Jun 2022

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years. 2. Inoperable, high-grade, epithelial ovarian carcinoma requiring perioperative chemotherapy (neoadjuvant and adjuvant). 3. Optical medical treatment (carboplatin-taxol chemotherapy every 3 weeks) and surgery at Institut Bergonié. 4. Non-clinically undernourished patient, i.e. without loss of more than 10% bodyweight in 6 months 5. Free, informed and written consent signed by the participant and the investigator (on the day of inclusion at the latest and before any tests required for the research). 6. Patient with social security cover in accordance with Article 1121-11 of the French code of public health. Exclusion Criteria: 1. Contraindication to CT-scans. 2. Contraindication to bone mineral densitometry. 3. Patients over the age of 70 the G8 of whom requires oncogeriatric surgery. 4. Patients under guardianship, vulnerable patients or patients under any other legal protection measures. 5. Geographic, social or psychological factors meaning the patient is unable to commit to study follow-up and procedures. 6. Patient already included in this study or in another study evaluating the impact of sarcopenia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High-grade epithelial ovarian carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian adenocarcinoma ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian carcinoma

Contacts and locations

Locations

  • Institut Bergonié

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.